LEADER 03078nam  2200625 a 450 
001 9910972624403321
005 20251017110056.0
010   $a0-309-22067-X
010   $a1-280-12334-6
010   $a9786613527202
010   $a0-309-22065-3
035   $a(CKB)2670000000176340
035   $a(OCoLC)794491570
035   $a(CaPaEBR)ebrary10554791
035   $a(SSID)ssj0000645747
035   $a(PQKBManifestationID)11380818
035   $a(PQKBTitleCode)TC0000645747
035   $a(PQKBWorkID)10683766
035   $a(PQKB)10169540
035   $a(MiAaPQ)EBC3378946
035   $a(Au-PeEL)EBL3378946
035   $a(CaPaEBR)ebr10554791
035   $a(CaONFJC)MIL352720
035   $a(OCoLC)785373830
035   $a(DNLM)1583262
035   $a(EXLCZ)992670000000176340
100   $a20120509d2012      uy         0
101 0 $aeng
135   $aurcn|||||||||
181   $ctxt
182   $cc
183   $acr
200 10$aFacilitating collaborations to develop combination investigational cancer therapies $eworkshop summary /$fMargie Patlak, Erin Balogh, and Sharyl J. Nass, rapporteurs ; Institute of Medicine of the National Academies
205   $a1st ed.
210   $aWashington, D.C. $cNational Academies Press$d2012
215   $a1 online resource (117 p.) 
300   $a"National Cancer Policy Forum, Board on Health Care Services."
311 08$a0-309-22064-5 
320   $aIncludes bibliographical references.
327   $aIntroduction -- Why Combinations and Collaborations Are Necessary -- Scientific Challenges in Developing Investigational Combination Therapies -- Overcoming Cultural Challenges to Collaborations  Legal Issues in Collaborations -- Financial Challenges -- Regulatory Issues -- Codevelopment of Therapies for HIV as a Model -- Examples of Collaborations Relevant to Cancer -- Wrapping Up --  Appendix A: Examples of Collaborations -- Appendix B: Workshop Agenda -- References -- Acronyms.
330   $a"Advances in biomedical research have increased our understanding of the complex nature of disease and the interaction of multiple molecular pathways involved in cancer. Combining investigational products early in their development is thought to be a promising strategy for identifying effective therapies. The IOM's National Cancer Policy Forum held a workshop to discuss challenges and identify potential solutions to improve collaboration and advance the development of combination investigational cancer therapies."--Publisher's description.
606   $aCancer$xTreatment
615  0$aCancer$xTreatment.
701   $aPatlak$b Margie$01607028
701   $aBalogh$b Erin$01089066
701   $aNass$b Sharyl J$0857626
712 02$aNational Cancer Policy Forum (U.S.)
712 02$aInstitute of Medicine (U.S.).$bBoard on Health Care Services.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910972624403321
996   $aFacilitating collaborations to develop combination investigational cancer therapies$94446112
997   $aUNINA